The ACTS Intervention to Reduce Breast Cancer Treatment Disparity
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01184066 |
|
Recruitment Status : Unknown
Verified March 2011 by University of Pittsburgh.
Recruitment status was: Recruiting
First Posted : August 18, 2010
Last Update Posted : March 9, 2011
|
Sponsor:
University of Pittsburgh
Collaborator:
West Penn Allegheny Health System
Information provided by:
University of Pittsburgh
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The 5-year survival after a first diagnosis of breast cancer is 13% lower in black than in white American women, an alarming disparity that cannot be explained by stage of disease at presentation. Nonadherence to breast cancer treatment and treatment delays from diagnosis to initiation of treatment may be among the reasons for worse breast cancer outcomes in black women. This recognition is critical because it suggests that breast cancer survival disparity can be decreased through clinical interventions that increase adherence to chemotherapy. The ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime, intensive psycho-educational intervention using a race-matched breast cancer survivor interventionist to: address Attitudes, including perceptions and stressors, that may impact adherence to clinical visits and treatment; encourage and model patient Communication with health care providers regarding physical and emotional needs, with attention to race-discordant situations; and provide tailored, understandable information about Treatment and its rationale. The Support component is threaded throughout the intervention via the presence of a race-matched breast cancer survivor and supportive video messages from the black community. This study is a randomized controlled trial that will test the efficacy of the ACTS Intervention vs. Usual Care on the primary outcomes of adherence to recommended breast cancer chemotherapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer | Behavioral: ACTS Intervention Behavioral: Usual Care | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 260 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | The ACTS Intervention to Reduce Breast Cancer Treatment Disparity |
| Study Start Date : | January 2010 |
| Estimated Primary Completion Date : | July 2014 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Breast cancer
MedlinePlus related topics:
Breast Cancer
| Arm | Intervention/treatment |
|---|---|
| Experimental: ACTS Intervention |
Behavioral: ACTS Intervention
ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence. |
| Active Comparator: Usual Care |
Behavioral: Usual Care
Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics. |
Primary Outcome Measures :
- Adherence to recommended breast cancer chemotherapy [ Time Frame: midpoint (6 or 12 weeks) and endpoint (12 or 24 weeks) of recommended chemotherapy regimen ]
Secondary Outcome Measures :
- Social Support [ Time Frame: baseline (0 weeks), midpoint (6 or 12 weeks), and endpoint (12 or 24 weeks) of recommended chemotherapy regimen ]
- Symptom Incidence [ Time Frame: baseline (0 weeks), midpoint (6 or 12 weeks), and endpoint (12 or 24 weeks) of recommended chemotherapy regimen ]
- Symptom Distress [ Time Frame: baseline (0 weeks), midpoint (6 or 12 weeks), and endpoint (12 or 24 weeks) of recommended chemotherapy regimen ]
- Communication of Symptoms [ Time Frame: baseline (0 weeks), midpoint (6 or 12 weeks), and endpoint (12 or 24 weeks) of recommended chemotherapy regimen ]
- Quality of Life [ Time Frame: baseline (0 weeks), midpoint (6 or 12 weeks), and endpoint (12 or 24 weeks) of recommended chemotherapy regimen ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- African American, as determined by patient self report on their demographic form completed at first medical oncology visit
- Female
- Age 18 or older
- Diagnosed with invasive breast cancer
- Recommended (prescribed) chemotherapy by participating medical oncologists
Exclusion Criteria:
- Impaired cognition, as determined by a score of less than 22 on the Mini Mental Status Exam
- An inability to understand English
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01184066
Contacts
| Contact: Margaret Q Rosenzweig, PhD, FNP-BC, AOCNP | 412-383-8839 | mros@pitt.edu |
Locations
| United States, Pennsylvania | |
| West Penn Allegheny Health System | Not yet recruiting |
| Pittsburgh, Pennsylvania, United States, 15224 | |
| Contact: Stephanie Kenney, CRA 412-359-4856 SKENNEY@wpahs.org | |
| Principal Investigator: Jane Raymond, MD | |
| Principal Investigator: Helen Analo, MD | |
| University of Pittsburgh | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15261 | |
| Contact: Margaret Q Rosenzweig, PhD 412-383-8839 mros@pitt.edu | |
| Contact: Rebecca N Dick, MS 412-648-8748 rnd4@pitt.edu | |
| Principal Investigator: Margaret Q Rosenzweig, PhD | |
Sponsors and Collaborators
University of Pittsburgh
West Penn Allegheny Health System
Investigators
| Principal Investigator: | Margaret Q Rosenzweig, PhD, FNP-BC, AOCNP | University of Pittsburgh |
| Responsible Party: | Margaret Quinn Rosenzweig, University of Pittsburgh School of Nursing |
| ClinicalTrials.gov Identifier: | NCT01184066 History of Changes |
| Other Study ID Numbers: |
706367 RSGT-09-150-01 CPHPS ( Other Grant/Funding Number: American Cancer Society ) |
| First Posted: | August 18, 2010 Key Record Dates |
| Last Update Posted: | March 9, 2011 |
| Last Verified: | March 2011 |
Keywords provided by University of Pittsburgh:
|
Chemotherapy Patient Adherence African Americans Cancer Survivor Decision Making |
Communication Quality of Life Social Support Patient Education |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |